KaiFu Pharmaceuticals develops small molecule drugs using an affinity detection by mass spectroscopy (ADMS) platform to identify and optimize compounds for treating tumors and autoimmune diseases. Their lead candidates, KF-0210 and KBP-2205, target unmet medical needs in oncology and have advanced to clinical trial stages, providing potential new therapies for patients.
Funding
$15.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Developing small molecule drugs for tumors and autoimmune diseases is challenging due to the difficulty in identifying and optimizing compounds with high affinity and specificity. Traditional drug screening methods can be time-consuming and may not effectively capture the complex interactions between drug candidates and their targets. This can lead to increased development risks and delays in bringing new therapies to patients.
Solution
KaiFu Pharmaceuticals utilizes an affinity detection by mass spectrometry (ADMS) platform to accelerate the discovery and development of small molecule drugs. The ADMS platform enables high-throughput screening of compounds, identifying those with strong affinity for specific drug targets relevant to tumors and autoimmune diseases. By integrating bioinformatics, chemical informatics, and computer-aided drug design, the platform facilitates intelligent drug screening and optimization, reducing development risks and accelerating the identification of differentiated drug candidates. This approach allows for the efficient development of innovative therapies addressing unmet medical needs.
Target Audience
The primary target audience includes patients with tumors and autoimmune diseases, as well as pharmaceutical companies and researchers seeking innovative small molecule drugs.
Features
- Affinity Detection by Mass Spectrometry (ADMS) platform for high-throughput screening of small molecule compounds.
- Integrated technologies including bioinformatics, chemical informatics, structural chemistry, and computer-aided drug design.
- Intelligent drug screening and optimization to accelerate the drug discovery process.
- Focus on small molecule innovative drugs for oncology and autoimmune diseases.
- Pipeline includes an EP4 receptor antagonist (KF-0210) in Phase Ib clinical trials for solid tumors and Phase II trials for osteoarthritis.
- KBP-2205, a second product targeting tumors, has completed PCC verification studies and has an approved IND.
- ADMS workstations capable of screening up to 250,000 compounds per day.
- Combines with AI to overcome the lack of experimental data for rapid verification faced by other AI-assisted new drug R&D technologies.